Integrated DNA Technologies, a Danaher company, has announced an expansion of its manufacturing operations at its Coralville campus, significantly increasing its production capacity for oligonucleotides used in advanced cancer research.

The expansion adds new production space and high-throughput equipment, resulting in more than a threefold increase in synthesis capacity. This enhancement is expected to accelerate the production of high-quality, customisable oligonucleotides, which are critical components in next-generation sequencing (NGS)-based oncology workflows, including Minimal Residual Disease (MRD) testing.

The upgraded facility is designed to improve manufacturing speed, flexibility and scalability, while maintaining strict quality and safety standards. The increased capacity allows researchers to access more tailored solutions, including variations in labelling, concentration, formulation and delivery formats, to meet complex research requirements.

This development complements IDT’s recent expansion of its research and development capabilities in Sunnyvale, strengthening its end-to-end capabilities in oncology, from assay innovation to large-scale manufacturing.

The company stated that the enhanced production capacity will support faster turnaround times and more efficient development of advanced genomic tools, including applications in multi-cancer early detection and precision diagnostics.

With over two decades of experience in next-generation sequencing technologies, IDT continues to play a key role in advancing genomics research. The company has also recently entered the clinical diagnostics space, marking a shift towards regulated applications and expanding its role in precision medicine.